Sarcoma

Sarcoma / 2006 / Article

Clinical Study | Open Access

Volume 2006 |Article ID 15947 | 4 pages | https://doi.org/10.1155/SRCM/2006/15947

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas

Received22 Jul 2005
Revised26 Jul 2006
Accepted17 Oct 2006
Published21 Nov 2006

Abstract

Introduction. The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear. We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were treated with single agent intravenous vinorelbine between April 1997 and December 2004. Doxorubicin had been administered previously to 53 subjects (91%), and the median number of lines of previous chemotherapy was 3 (range 0–7). Results. Patients received a median 6 doses of vinorelbine (range 1–65). The overall response rate was 6% (3 patients: 1 angiosarcoma, 1 epithelioid sarcoma, and 1 embryonal rhabdomyosarcoma). Fourteen patients (26%) experienced a best result of stable disease. Median time to progression was 1.8 months (95% confidence intervals 1.5–2.1 months, Kaplan-Meier estimate). Eight patients experienced grade 3 or 4 toxicity, most commonly febrile neutropenia. Conclusion. Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients. Prospective investigation may be considered for selected sarcoma subtypes.

References

  1. A Jemal, R Siegel, E Ward et al., “Cancer statistics, 2006,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006. View at: Google Scholar
  2. M F Brennan, S Singer, R G Maki, and B O'Sullivan, “Soft tissue sarcoma,” in Cancer: Principles & Practice of Oncology, V T Jr DeVita, S Hellman, and S A Rosenberg, Eds., pp. 1581–1637, Lippincott Williams & Wilkins, Philadelphia, Pa, 7th edition, 2005. View at: Google Scholar
  3. K H Antman and A D Elias, “Chemotherapy of advanced soft-tissue sarcomas,” Seminars in Surgical Oncology, vol. 4, no. 1, pp. 53–58, 1988. View at: Google Scholar
  4. L Svancarova, J Y Blay, I R Judson et al., “Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 38, no. 4, pp. 556–559, 2002. View at: Publisher Site | Google Scholar
  5. M L Hensley, R G Maki, E Venkatraman et al., “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824–2831, 2002. View at: Publisher Site | Google Scholar
  6. J A Gottlieb, R S Benjamin, L H Baker et al., “Role of DTIC (NSC-45388) in the chemotherapy of sarcomas,” Cancer Treatment Reports, vol. 60, no. 2, pp. 199–203, 1976. View at: Google Scholar
  7. M Casanova, A Ferrari, F Spreafico et al., “Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma,” Cancer, vol. 94, no. 12, pp. 3263–3268, 2002. View at: Publisher Site | Google Scholar
  8. G Nasti, D Errante, R Talamini et al., “Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study,” Journal of Clinical Oncology, vol. 18, no. 7, pp. 1550–1557, 2000. View at: Google Scholar
  9. P Fidias, G Demetri, and D Harmon, “Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner's Cancer Care Study,” Proceedings of the American Society for Clinical Oncology, vol. 17, p. 1977, 1998. View at: Google Scholar
  10. M Van Glabbeke, J Verweij, I Judson, and O S Nielsen, “EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas,” European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002. View at: Publisher Site | Google Scholar
  11. K M Leu , L J Ostruszka, D Shewach et al., “Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1706–1712, 2004. View at: Publisher Site | Google Scholar
  12. J O Bay, I Ray-Coquard, J Fayette et al., “Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis,” International Journal of Cancer, vol. 119, no. 3, pp. 706–711, 2006. View at: Publisher Site | Google Scholar
  13. R G Maki, M L Hensley, J K Wathen et al., “A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS),” Journal of Clinical Oncology, vol. 24, no. 18S, p. 9514, 2006. View at: Google Scholar
  14. F Grosso, G D Demetri, J-Y Blay et al., “Patterns of tumor response to trabectedin (ET-743) in myxoid liposarcomas,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 9511, 2006. View at: Google Scholar

Copyright © 2006 Sibyl E. Anderson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

0 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.